InoLife Technologies, Inc. (INOL.OB) to Market a Plavix Metabolizing Test to Physicians and Practitioners
InoLife Technologies, Inc., a service-based healthcare products development, integration and marketing company, recently announced that it will market its proprietary metabolizing test to physicians and practitioners to identify how a patient’s genetic makeup may affect the body's response to Plavix (colpidogrel). Plavix, the second-best selling drug in the world, reduces the risk of heart attack, stroke, and cardiovascular death in patients with cardiovascular disease by making platelets less likely to form blood clots. The Food and Drug Administration recently announced that Plavix must now carry a so-called “black box” warning label after a study revealed that patients with genetic variation…